Author Correction: GLP-1-based therapies for diabetes, obesity and beyond
Nature Reviews Drug Discovery, Published online: 28 May 2025; doi:10.1038/s41573-025-01231-3 Author Correction: GLP-1-based therapies for diabetes, obesity and beyond
Weight-loss drugs may lower risk of obesity-related cancers
Popular GLP-1 weight-loss drugs like Ozempic and Zepbound can help reduce a woman’s risk for as many as 14 cancers associated with obesity, a new study says.
Weight-Loss Drugs May Lower Risk Of Obesity-Related Cancers
By Dennis Thompson HealthDay ReporterWEDNESDAY, May 28, 2025 (HealthDay News) — Popular GLP-1 weight loss drugs like Ozempic and Zepbound can help…
Novo Nordisk’s 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?
Nothing attracts competition like the opportunity for profits, and the weight loss drug market has become arguably the healthcare industry’s hottest opportunity in recent memory. Novo Nordisk (NYSE: NVO) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy. However, competition is picking up with multiple next-generation drugs working through clinical testing. […]
Can GLP-1s Protect Against Obesity-Related Cancers?
GLP-1 receptor agonists may modestly reduce the risk for 14 obesity-related cancers, especially colorectal cancer, among adults with obesity and diabetes, new data suggest. Medscape Medical News
Patenting Privation (Part III): Empowering Revenge
Just over a year ago on these pages, I continued our look at the patent franchises protecting the defining drugs of our time, Novo Nordisk and Eli Lilly’s diabetes/weight-loss blockbusters, Ozembic/Wegovy and Mounjaro/Zepbound. As you can imagine with drugs of such culture-defining magnitude, the year that has passed since that column has been full of […]
Scientists Discovered The “Missing” Amino Acid That Triggered 30% Weight Loss in Just One Week
According to the World Health Organization, adult obesity has more than doubled since the 1990s, while adolescent obesity has quadrupled. Despite various diet strategies like low-carb and low-fat plans, GLP-1 medications, and different exercise routines aimed at reducing obesity, the numbers continue to rise with no clear end in sight. However, a new study suggests […]
MCED Test Performance in Obese Individuals
This abstract evaluates a multi-cancer early detection (MCED) blood test specifically designed for individuals with obesity, a group at higher risk for several cancers often without standard screening. The study investigated the test’s ability to accurately detect cancer and identify the tissue of origin using a two-step methylation profiling method. Results showed the test had a high positive predictive value (PPV) and reasonable sensitivity, […]
End of Compounded Semaglutide; 464M Teens Will Have Obesity; GLP-1 Scripts Skyrocket
(MedPage Today) — A federal deadline ending the sale of compounded semaglutide (Ozempic, Wegovy) is now in effect after a similar one for tirzepatide (Mounjaro, Zepbound) passed in March. (U.S. News & World Report) A patient-delivered lifestyle…
Glucagon-like peptide 1 level and risk of death within 90 days after intensive care unit admission: A substudy of the IVOIRE cohort
by Marine Jacquier, Annabelle Tavernier, Jean-Pierre Quenot, David Masson, Elea Ksiazek, Isabelle Fournel, Jacques Grober Background Elevated plasma levels of glucagon-like peptide-1 (GLP-1) have been associated with poor clinical outcome in patients with sepsis. This study investigated the association between GLP-1 levels, and survival at 90 days in a large cohort of critically ill patients. […]